IMP: 2025 Annual Report
Filed with HOSE · · 146 pages · English
Summary by 6ix AI
The report details the company's achievements, including maintaining its leading position in the antibiotic market and launching Vietnam's first EU-GMP standard generic antibiotic.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Imexpharm’s 2025 Annual Report revolves around the theme “The Rhythm of Health” (Nhịp Khỏe), reflecting the Company’s harmonious and resilient momentum amid a volatile business environment. “Rhythm” represents strategic agility, operational flexibility, and the ability to stay attuned to the movements of the times, responding promptly to the increasingly diverse healthcare needs of the community.
Story so far
Earlier from Imexpharm
- IMP: Record date for 2025 cash dividend payment
- IMP: Notice of the record date for 2025 cash dividend payment
- IMP: Approval of the record date for 2025 cash dividend payment
- IMP: Change in personnel
- IMP: Signing an audit contract for the 2026 financial statements
Later from Imexpharm
- IMP: Report on Corporate Governance for the first half of 2026
- IMP: The Board resolution dated September 7, 2026
- IMP: Update Regulations on Supervision and Approval of related party transactions
- IMP: Update Regulations on the Internal Audit
- IMP: Update Regulations on the Operation of the audit & Risk Management Committee
Follow Imexpharm into a list and get an email when it puts out news.
Follow Imexpharm